K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
173
[21] E.J. Scollon, J.M. Starr, S.J. Godin, M.J. DeVito, M.F. Hughes, In vitro metabolism
of pyrethroid pesticides by rat and human hepatic microsomes and cytochrome
P450 isoforms, Drug Metab. Dispos. 37 (2009) 221–228.
[39] M.J. Trevisan, L.R.P. Trevizan, G.C. de Baptista, A.A. Franco, Metabolism of carbo-
sulfan to carbofuran and to 3-hydroxy-carbofuran in orange leaves, Rev. Bras.
Toxicol. 17 (2004) 17–22.
[22] J.C. Lipscomb, T.S. Poet, In vitro measurements of metabolism for application
in pharmacokinetic modeling, Pharmacol. Ther. 118 (2008) 82–103.
[23] O. Pelkonen, E.H. Kaltiala, T.K.I. Larmi, N.T. Karki, Cytochrome P 450 linked
monooxygenase system and drug induced spectral interactions in human liver
microsomes, Chem. Biol. Interact. 9 (1974) 205–216.
[24] M.M. Bradford, A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding, Anal.
Biochem. 72 (1976) 248–254.
[40] Y. Kinoshita, T.R. Fukuto, Insecticidal properties of N-sulfonyl derivatives of
propoxur and carbofuran, J. Agric. Food Chem. 28 (1980) 1325–1327.
[41] R.T. Goad, J.T. Goad, B.H. Atieh, R.C. Gupta, Carbofuran-induced endocrine dis-
ruption in adult male rats, Toxicol. Mech. Methods 14 (2004) 233–239.
[42] C. Wesseling, M. Keifer, A. Ahlbom, R. McConnell, J.D. Moon, L. Rosen-
stock, C. Hogstedt, Long-term neurobehavioral effects of mild poisonings with
organophosphate and n-methyl carbamate pesticides among banana workers,
Int. J. Occup. Environ. Health 8 (2002) 27–34.
[25] M.D. Burke, R.A. Prough, R.T. Mayer, Characteristics of
a
microsomal
[43] O. Pelkonen, J. Maenpaa, P. Taavitsainen, A. Rautio, H. Raunio, Inhibition and
induction of human cytochrome P450 (CYP) enzymes, Xenobiotica 28 (1998)
1203–1253.
cytochrome P-448-mediated reaction. Ethoxyresorufin O-de-ethylation, Drug
Metab. Dispos. 5 (1977) 1–8.
[26] W.F. Greenlee, A. Poland, An improved assay of 7-ethoxycoumarin O-
deethylase activity: induction of hepatic enzyme activity in C57BL/6J
and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-
tetrachlorodibenzo-p-dioxin, J. Pharmacol. Exp. Ther. 205 (1978) 596–
605.
[44] R.J. Riley, A.J. Parker, S. Trigg, C.N. Manners, Development of a generalized,
quantitative physicochemical model of CYP3A4 inhibition for use in early drug
discovery, Pharm. Res. 18 (2001) 652–655.
[45] Y. Liu, H. Hao, C. Liu, G. Wang, H. Xie, Drugs as CYP3A probes, inducers, and
inhibitors, Drug Metab.Rev. 39 (2007) 699.
[27] H. Raunio, J. Valtonen, P. Honkakoski, M.A. Lang, M. Stahlberg, M.A. Kairaluoma,
A. Rautio, M. Pasanen, O. Pelkonen, Immunochemical detection of human liver
cytochrome P450 forms related to phenobarbital-inducible forms in the mouse,
Biochem. Pharmacol. 40 (1990) 2503–2509.
[28] M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, O. Pelko-
nen, Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in
human liver microsomes in vitro, Drug Metab. Dispos. 32 (2004) 626–
631.
[29] X. Li, A. Bjorkman, T.B. Andersson, M. Ridderstrom, C.M. Masimirembwa,
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is medi-
ated by CYP2C8: A new high affinity and turnover enzyme-specific probe
substrate, J. Pharmacol. Exp. Ther. 300 (2002) 399–407.
[30] T.H. Sullivan-Klose, B.I. Ghanayem, D.A. Bell, Z.Y. Zhang, L.S. Kaminsky, G.M.
Shenfield, J.O. Miners, D.J. Birkett, J.A. Goldstein, The role of the CYP2C9-Leu359
allelic variant in the tolbutamide polymorphism, Pharmacogenetics 6 (1996)
341–349.
[31] T. Kronbach, D. Mathys, J. Gut, T. Catin, U.A. Meyer, High-performance
liquid chromatographic assays for bufuralol 1’-hydroxylase, debrisoquine
4-hydroxylase, and dextromethorphan O-demethylase in microsomes and
purified cytochrome P-450 isozymes of human liver, Anal. Biochem. 162 (1987)
24–32.
[32] R. Peter, R. Bocker, P.H. Beaune, M. Iwasaki, F.P. Guengerich, C.S. Yang, Hydrox-
ylation of chlorzoxazone as a specific probe for human liver cytochrome
P-450IIE1, Chem. Res. Toxicol. 3 (1990) 566–573.
[33] T. Kronbach, D. Mathys, M. Umeno, F.J. Gonzalez, U.A. Meyer, Oxidation of mida-
zolam and triazolam by human liver cytochrome P450IIIA4, Mol. Pharmacol.
36 (1989) 89–96.
[34] A. Abelo, T.B. Andersson, M. Antonsson, A.K. Naudot, I. Skanberg, L. Wei-
dolf, Stereoselective metabolism of omeprazole by human cytochrome P450
enzymes, Drug Metab. Dispos. 28 (2000) 966–972.
[46] T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, V. Fischer,
R. Tyndale, T. Inaba, W. Kalow, H.V. Gelboin, F.J. Gonzalez, Cytochrome P-
450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially
expressed in adult human liver. cDNA and deduced amino acid sequence and
distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism
of steroid hormones and cyclosporine, J. Biol. Chem. 264 (1989) 10388–10395.
[47] A.D. Rodrigues, Integrated cytochrome P450 reaction phenotyping. Attempt-
ing to bridge the gap between cDNA-expressed cytochromes P450 and native
human liver microsomes, Biochem. Pharmacol. 57 (1999) 465–480.
[48] R. Kitamura, K. Sato, M. Sawada, S. Itoh, M. Kitada, M. Komori, T. Kamataki,
Stable expression of cytochrome P450IIIA7 cDNA in human breast cancer cell
line MCF-7 and its application to cytotoxicity testing, Arch. Biochem. Biophys.
292 (1992) 136–140.
[49] J. Hakkola, H. Raunio, R. Purkunen, S. Saarikoski, K. Vähäkangas, O. Pelkonen,
R.J. Edwards, A.R. Boobis, M. Pasanen, Cytochrome P450 3A expression in the
human fetal liver: evidence that CYP3A5 is expressed in only a limited number
of fetal livers, Biol. Neonate 80 (2001) 193–201.
[50] J. Tang, Y. Cao, R.L. Rose, A.A. Brimfield, D. Dai, J.A. Goldstein, E. Hodgson,
Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human,
mouse, and rat liver microsomes, Drug Metab. Dispos. 29 (2001) 1201–1204.
[51] J. Tang, Y. Cao, R.L. Rose, E. Hodgson, In vitro metabolism of carbaryl by human
cytochrome P450 and its inhibition by chlorpyrifos, Chem. Biol. Interact. 141
(2002) 229–241.
[52] E. Mutch, A.K. Daly, J.B. Leathart, P.G. Blain, F.M. Williams, Do multiple
cytochrome P450 isoforms contribute to parathion metabolism in man? Arch.
Toxicol. 77 (2003) 313–320.
[53] E. Mutch, F.M. Williams, Diazinon, chlorpyrifos and parathion are metabolised
by multiple cytochromes P450 in human liver, Toxicology 224 (2006) 22–32.
[54] M. Turpeinen, C. Ghiciuc, M. Opritoui, L. Tursas, O. Pelkonen, M. Pasanen, Pre-
dictive value of animal models for human cytochrome P450 (CYP)-mediated
metabolism: A comparative study in vitro, Xenobiotica 37 (2007) 1367–1377.
[55] A. Falk-Filipsson, A. Hanberg, K. Victorin, M. Warholm, M. Wallén, Assessment
factors—applications in health risk assessment of chemicals, Environ. Res. 104
(2007) 108–127.
[56] B. Meek, A. Renwick, C. Sonich-Mullin, Practical application of kinetic data in
risk assessment—an IPCS initiative, Toxicol. Lett. 138 (2003) 151–160.
[57] WHO/IPCS, Chemical-specific adjustment factors for interspecies differ-
ences and human variability: guidance document for use of data in
dose/concentration-response assessment. International Program on Chemical
Safety, WHO/UNEP/ILO, World Health Organization, Geneva, 2005.
[58] A.G. Renwick, N.R. Lazarus, Human variability and noncancer risk assessment—
an analysis of the default uncertainty factor, Regul. Toxicol. Pharm. 27 (1998)
3–20.
[35] M. Turpeinen, J. Uusitalo, J. Jalonen, O. Pelkonen, Multiple P450 substrates in a
single run: rapid and comprehensive in vitro interaction assay, Eur. J. Pharm.
Sci. 24 (2005) 123–132.
[36] A. Tolonen, A. Petsalo, M. Turpeinen, J. Uusitalo, O. Pelkonen, In vitro interac-
tion cocktail assay for nine major cytochrome P450 enzymes with 13 probe
reactions and a single LC/MSMS run: analytical validation and testing with
monoclonal anti-CYP antibodies, J. Mass Spec. 42 (2007) 960–966.
[37] J.H. Kim, C. Chang, J. Moon, H. Lee, J. Lee, H. Park, B. Park, E. Hwang, H. Lee, K.
Liu, Comparative metabolism of insecticide carbosulfan by human, mouse and
rat liver microsomes, Toxicol. Lett. 172 (2007) S211–S1211.
[38] A. Rostami-Hodjegan, A. Rostami-Hodjegan, G.T. Tucker, Simulation and pre-
diction of in vivo drug metabolism in human populations from in vitro data,
Nat. Rev. Drug Discov. 6 (2007) 140–148.